IGC Pharma, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

IGC$0.20+2.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share data)

	June 30, 2026 (Unaudited) ($)	December 31, 2025 (Audited) ($)
ASSETS
Current assets:
Cash and cash equivalents	331	900
Accounts receivable, net	56	12
Inventory	640	640
Current investment	23	38
Deposits and advances	214	200
Total current assets	1,264	1,790
Non-current assets:
Intangible assets, net	5,507	5,101
Property, plant, and equipment, net	2,069	2,141
Claims and advances	656	669
Operating lease asset	-	11
Total non-current assets	8,232	7,922
Total assets	9,496	9,712
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	1,618	1,014
Accrued liabilities and others	664	962
Current loans	933	180
Total current liabilities	3,215	2,156
Non-current liabilities:
Non-current loans	149	131
Operating lease liability	-	2
Total non-current liabilities	149	133
Total liabilities	3,364	2,289
Stockholders’ equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of June 30, 2026, and December 31, 2025.
Common stock and additional paid-in capital, $0.0001 par value: 600,000,000 shares authorized; 102,417,178 and 95,038,026 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively.	142,065	138,014
Accumulated other comprehensive loss	(5,705)	(5,701)
Accumulated deficit	(130,228)	(124,890)
Total stockholders’ equity	6,132	7,423
Total liabilities and stockholders’ equity	9,496	9,712

| June 30, 2026, Form 10-Q

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.